Outlook Therapeutics raises ~$55M in public offering of common stock and warrants

Outlook Therapeutics, Inc.

55,555,556 shares and warrants sold at $0.99 combined; gross proceeds ~$55M.
Warrants exercisable at $1.10/share, expire in 5 years; underwriters' option for 8.33M additional warrants exercised.
GMS Ventures (largest stockholder) bought 2,525,252 shares; CEO Robert Jahr and CFO Lawrence Kenyon bought 151,515 and 101,010 shares respectively.
Offering expected to close Aug 14, 2026; Piper Sandler and BTIG are underwriters.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.